DECLARATION OF INTERESTS

All 15 SAGE members participating in the meeting updated their declaration of interest ahead of the meeting. 12 SAGE members reported relevant interests, which were assessed not to constitute a conflict of interest in relation to the meeting agenda. It was assessed that all members could fully participate in the meeting.

All the reported relevant interests are summarized below:

SAGE Members
Rebecca Grais

- Serves as a Scientific Advisory Committee member on CEPI. This interest was perceived as non-personal, non-specific and financially insignificant*.
- Serves as a member at Institut Pasteur Dakar, MADIBA Project Steering Committee. This interest was perceived as non-personal, non-specific and financially insignificant*.
- Serves as sponsor of fractional dose PCV, phase IV trial, funded by EDCTP. This interest was perceived as non-personal, non-specific and financially significant*.
- Serves as sponsor of fractional dose yellow fever, phase IV, funded by welcome trust, MSF foundation. This interest was perceived as non-personal, non-specific and financially insignificant*.
- Served until November 2022 as site investigator for effectiveness of Ebola vaccine, Phase II/III, funded by CEPI. This interest was perceived as non-personal, non-specific and financially insignificant*.
- Served until 2023 as a DSMB member on Serum Institute of India for yellow fever vaccine. This interest was perceived as non-personal, non-specific and financially insignificant*.
- Served until 2023 as a DSMB member on Scandenavian Bio Pharma/EDCTP. This interest was perceived as non-personal, non-specific and financially insignificant*.
• Served in 2023 on the IVI Expert Panel on Hepatitis E vaccine in pregnant women. This interest was perceived as non-personal, specific and financially insignificant*.

**Gabriel Leung**

• Serves on the advisory panel on COVID-19 Vaccines, Government of Hong Kong SAR. This interest was perceived as non-personal, specific and financially insignificant*.

**Saad Omer**

• Serves as a member on the Board of Trustees of the Sabin Vaccine Institute. This interest was perceived as non-personal, non-specific and financially insignificant*.
• Serves as a member on Gavi the Vaccine Alliance Board. This interest was perceived as non-personal, non-specific and financially insignificant*.
• Serves as a member on Gavi Programme and Policy Committee, This interest was perceived as non-personal, non-specific and financially insignificant*.
• Serves as a member on the US National Vaccine Advisory Committee (NVAC) Working Group for Vaccine Hesitancy. This interest was perceived as non-personal, non-specific and financially insignificant*.
• Serves on the Lancet Commission on Vaccines in the USA. This interest was perceived as non-personal, non-specific and financially insignificant*.
• Serves on WHO Group B Strep Value Proposition Technical Working Group. This interest was perceived as non-personal, non-specific and financially insignificant*.
• Serves on WHO Expert Steering Committee on Safety Surveillance in Pregnancy in LMIC. This interest was perceived as non-personal, non-specific and financially insignificant*.
• Serves on WHO Technical Advisory Group on Behavioral Insights and Sciences for Health. This interest was perceived as non-personal, non-specific and financially insignificant*.
• Affiliation to the Office of Evaluation Sciences (White House Social and Behavioral Sciences Team) until 2021. This interest was perceived as non-personal, non-specific and financially insignificant*.
• Serves as a member for National Academies of Sciences, Engineering, and Medicine, Committee on Equitable Allocation of Vaccines for the Novel
Coronavirus. This interest was perceived as non-personal, specific and financially insignificant*.

- Serves as temporary voting member for Food and Drug Administration Center for Biologics Evaluation and Research 181st Vaccines and Related Biological Products Advisory Committee. This interest was perceived as non-personal, non-specific and financially insignificant*.

- Serves as principal investigator for Hepatitis B Vaccine Induced Immunity in Neonates pilot study. The study is funded by NIH. This interest was perceived as non-personal, non-specific and financially insignificant*.

- Serves as supervisor-lead for P3-MumBubVax clinical trials. This interest was perceived as non-personal, non-specific and financially insignificant*.

- Served until 2022 as a consultant for Bill & Melinda Gates Foundation for pooled analysis for three maternal influenza vaccines. This interest was perceived as personal, non-specific and financially significant*.

- Serves as principal investigator in the research unit funded by Facebook omer, on evaluating vaccine acceptance messages using social media, This interest was perceived as personal, non-specific and financially significant*.

- Served as faculty in META, digital media for health outcome, This interest was perceived as non-personal, non-specific and financially significant*.

- Served until 2022 as a member in Rockefeller’s global immunization initiative advisory council to advise them on vaccine acceptance initiatives. This interest was perceived as non-personal, non-specific and financially significant*.

- Served until 2022 as a faculty on Medscape Steering Committee for the COVID-19 Vaccination Education Center. This interest was perceived as personal, specific and financially significant*.

- Served until 2021 as a member of national academies of sciences, engineering, and medicine rapid expert consultation (REC) on building vaccine confidence in COVID-19 vaccines. This interest was perceived as non-personal, non-specific and financially insignificant*.

- Served until 2021 as a member of national academies of sciences, engineering, and medicine, committee on addressing issues of vaccine distribution and supply chains to advance pandemic and seasonal influenza preparedness and response. This interest was perceived as non-personal, non-specific and financially insignificant*. 
Served until 2021 as a member of WHO measuring behavioral and social drivers of vaccination working group. This interest was perceived as non-personal, non-specific and financially insignificant*.

Served until 2021 as chair of WHO, global advisory committee on vaccine safety working group on COVID-19 vaccine safety preparedness. This interest was perceived as non-personal, non-specific and financially insignificant*.

Cristiana Toscano

Serves as a member in Brazilian NITAG. This interest was perceived as personal, specific and financially insignificant*.

Serves as a member of the Advisory group of experts for Fiocruz on COVID vaccine development. This interest was perceived as personal, specific and financially insignificant*.

Served on the PAHO TAG until 2024. This interest was perceived as non-personal, non-specific and financially insignificant*.

Her institution receives funding from PAHO to provide technical support to research Project on PCV Impact in Latin America. This interest was perceived as non-personal, non-specific and financially significant*.

Her institution receives funding from PAHO to provide Technical support to evaluate COVID vaccine impact and effectiveness in latin American Countries. This interest was perceived as non-personal, specific and financially significant*.

Her institution received funding from Gavi and R4 for Capacity building activities to immunization teams in Lusophone countries in Africa transitioning from GAVI support, and Linked collaborative learning network on immunization supported by GAVI. This interest was perceived as non-personal, non-specific and financially significant*.

Her institution received funding until 2023 from Results for Development (R4D) to support to support for implementing and evaluating a capacity building program for immunization team in Angola. This interest was perceived as non-personal, non-specific and financially significant*.

Research support received from CNPq - Brazilian National Council for Technological Research until 2023 for COVID epidemiology and modelling research to support decision making during the pandemic. This interest was perceived as non-personal, specific and financially significant*.
Shabir Madhi

- Serves as member of CEPI, PSMB. This interest was assessed as personal, non-specific and financially insignificant*.
- Serves as a member of the BMGF global health scientific advisory committee. This interest was assessed as non-personal, non-specific and financially insignificant*.
- Serves as a member of RIGHT foundation Scientific Advisory board. This interest was assessed as non-personal, non-specific and financially insignificant*.
- His institution receives grants from MSD for the study of Pneumococcal conjugate vaccine. This interest was assessed as non-personal, non-specific and financially insignificant*.
- His institution received in 2023 the grants for Pfizer symposium on RSV epidemiology. This interest was assessed as non-personal, specific and financially insignificant*.
- His institution received in 2022 grants for GSK symposium on Pneumococcus and viruses. This interest was assessed as non-personal, non-specific and financially insignificant*.
- Serves as Principal Investigator on COVID-19 and GBS, funded through BMGF. This interest was assessed as non-personal, specific and financially significant*.
- Serves as Principal Investigator to conduct studies on GBS and RSV funded through Pfizer. This interest was assessed as non-personal, specific and financially significant*.
- Serves as Principal Investigator on RSV studies, funded through GSK. This interest was assessed as non-personal, specific and financially significant*.
- Served as Principal Investigator until 2023 on RSV and COVID-19 studies, funded through Novavax. This interest was assessed as non-personal, non-specific and financially significant*.
- Served as Principal Investigator until 2022 on RSV monoclonal antibody study, funded through Medimmune/AstraZeneca. This interest was assessed as non-personal, non-specific and financially significant*.
- Serves as Principal Investigator on RSV monoclonal antibody study, funded through MSD. This interest was assessed as non-personal, non-specific and financially significant*.
• His institution received until 2022 a research grant from Pfizer related to GBS. This interest was assessed as non-personal, non-specific and financially significant*.

• His institution receives a research grant from Minervax related to GBS. This interest was assessed as non-personal, non-specific and financially significant*.

• His institution receives multiple research grant from BMGF on pneumococcal conjugate vaccine, Group b streptococcus vaccine, Covid-19 vaccine and epidemiology studies on under-5 childhood deaths and pneumonia. This interest was assessed as non-personal, specific and financially significant*.

Peter McIntyre

• Serves as Principal investigator on ACTRN for Measuring and strengthening immunity to measles in young adults fully immunised in childhood – RCT, funded by Health Research Council New Zealand. This interest was assessed as personal, non-specific and financially significant*.

• Serves as investigator on Australian Indo-Pacific Centre research grant: “Mitigating health security risks by supporting immunisation coverage and preventing outbreaks”. This interest was assessed as non-personal, non-specific and financially significant*.

• Serves as investigator on National Health and Medical Research Council Partnership Grant: Reducing vaccine preventable diseases in children: using national active hospital-based surveillance to evaluate and improve immunisation program performance. This interest was assessed as non-personal, non-specific and financially significant*.

• Serves as co-Principal Investigator on “Influenza in a post-COVID world” University of Auckland, Funded by FluLab, a philanthropic trust based in the United States. This interest was assessed as personal, non-specific and financially significant*.

• Serves as investigator National Health and Medical Research Council Centre for Research Excellence: Accelerating introduction of pneumococcal conjugate vaccines in the Asia-Pacific region. This interest was assessed as non-personal, non-specific and financially significant*.

• Served until 2022 as a member of the DSMB for the Novavax Covid-19 vaccine. This interest was assessed as non-personal, specific and financially insignificant*.
• Served until 2023 as a member of the New Zealand Scientific and TAG on COVID-19 vaccines. This interest was assessed as non-personal, specific and financially insignificant*.

• Served until 2021 as lead investigator on Otago Medical Research Foundation Grant NZ: Immunity to measles in young adults: is it waning and does it matter?”. This interest was assessed as non-personal, non-specific and financially significant*.

Kim Mulholland

• Serves as principal investigator PCV trial in Vietnam, funded by the Gavi Alliance and the Bill and Melinda Gates Foundation. This interest was assessed as non-personal, non-specific and financially significant*.

• Serves as Co-PI on HPV trial in Viet Nam, funded by UKRI. This interest was assessed as non-personal, non-specific and financially significant*.

• Serves as co-investigator on a study of the effectiveness of typhoid conjugate vaccine in Fiji, funded by Korea philanthropy. This interest was assessed as non-personal, non-specific and financially significant*.

• Serves as principal investigator on Covid-19 trial in Mongolia, Indonesia, Australia, funded by CEPI. This interest was assessed as non-personal, specific and financially significant*.

• Serves as Principal Investigator on a study of HPV introduction evaluation in Ethiopia, funded by UKRI and BMGF. This interest was assessed as non-personal, non-specific and financially significant*.

• Serves as collaborative member of an observational study of adult pneumonia in Mongolia, funded by Pfizer. This project is led by a member of my group. This interest was perceived as non-personal, non-specific and financially insignificant *.

• Serves as investigator on an evaluation of PCV schedules in Nha Trang in Vietnam funded by the Bill and Melinda Gates Foundation. This interest was assessed as non-personal, specific and financially significant*.

• Serves as principal investigator on HPV detection in young women 5 years following the 4-valent HPV vaccine in Mongolia funded by Australian embassy in Mongolia. This interest was assessed as non-personal, non-specific and financially significant*.

• Serves as a member on ISPPD board. This interest was perceived as personal, non-specific and financially insignificant *.
• Served as Principal Investigator until 2023 on a study of HPV vaccination of female sex workers in Vietnam, funded by UKRI. This interest was assessed as non-personal, non-specific and financially significant*.

• Served until 2022 as principal investigator on the evaluation of the impact of PCV in Mongolia funded by GAVI. This interest was assessed as non-personal, specific and financially significant*.

• Served until 2021 as Novavax DSMB for Covid-19 vaccine trials in Australia and South Africa. This interest was perceived as non-personal, specific and financially insignificant*

Kathleen Neuzil

• Serves as a member of the Board of Directors for the US National Foundation of Infectious Diseases. This interest was perceived as non-personal, non-specific and financially insignificant*.

• Served until 2021 as an investigator on a grant from University of Washington for a COVID-19 post-exposure prophylaxis study of hydroxychloroquine. This interest was perceived as non-personal, specific and financially significant*.

• Served as Co-chair of the NIH COVID Vaccine Prevention Network until 2022, which serves as the focal point for USG sponsored trials in COVID-19 vaccines and monoclonal antibodies. This Network is supported through an NIH grant for the leadership of the Vaccine Treatment and Evaluation Units. This interest was perceived as non-personal, specific and financially significant*.

• Served as principal investigator for the NIH funded NIH T32 Fellowship Training Program in Vaccinology until 2023. This interest was perceived as non-personal, non-specific and financially significant*.

• Serves as PI for NIH-funded Collaborative Influenza Vaccine Innovation Center (CIVICs) program. This interest was perceived as non-personal, non-specific and financially significant*.

• Serves as principal investigator for the Bill and Melinda Gates Foundation-funded Typhoid Vaccine Acceleration Consortium (2016-2021 and extension 2021-2025), which includes clinical studies of Bharat Biotech, India Typbar-TCV. This interest was perceived as non-personal, non-specific and financially significant*.

• Serves as principal investigator for the NIAID/NIH funded Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever.
This interest was perceived as non-personal, non-specific and financially significant*.

- Serves a principal investigator for the Vaccine Company, Inc. funded “A Phase 1, Open-label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of DCFHP-Alum, A Spike-Functionalized Ferritin Nanoparticle Vaccine Targeting COVID-19, Col-formulated with Aluminum Hydroxide Adjuvant, in Healthy Adults in the United States”. This interest was perceived as non-personal, non-specific and financially insignificant*.

- Her institution receives research support for the following studies. These interests were perceived as non-personal, non-specific and financially significant*.
  - Safety and reactogenicity of HTNV, PUUV, and combination HTNV/PUUV DNA vaccine from Geneva Foundation.
  - Double-blind, Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety, Tolerability, Efficacy, and Immunogenicity of a 2-Dose and 3-Dose Regimen of V160, Human Cytomegalovirus (HCMC) Vaccine in Healthy Seronegative Adolescent and Adult Women 16-35 Years of Age funded by Merck.
  - Longitudinal Antibody Profile Correlated with Protection from Malaria in Malawi – Sponsor - Boston University.
  - DON in Pediatric Cerebral Malaria: A Phase 1 Dose-Escalation Safety Study – Sponsor- Children’s Research Institute/NIH.
  - Vaccine Treatment Evaluation Unit (VTEU) Clinical Site: DMID 19-0007; Exposure-Response Evaluation of IV Artesunate in Children with Severe Malaria – Sponsor – NIAID/NIH.
  - VTEU 13-0088: A Phase 1 Challenge Study to Evaluate Safety, Immunogenicity, and Efficacy of a Malaria Vaccine (rCSP adjuvanted with AP 10-602 [GLA-LSQ]), in Health Adults – Sponsor – NIAID/NIH.
  - Dose Escalation Study Of Sanaria’s Irradiated Sporozoite Vaccine (PfSPZ Vaccine), Followed By A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial to Evaluate The Safety And Immunogenicity Of PfSPZ Vaccine in Malaria-Experienced Adults in Burkina Faso – Sponsor – NIAID/NIH.
  - Development of Malaria Vaccine Candidate VLPM01, Phase 2 – Sponsor – Maryland Industrial Partnerships (MIPS).
Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease Vaccine – Sponsor – Seek, UK.

“An exploratory Phase I, randomized, observer-blind, placebo-controlled dose escalation trial evaluating the safety, tolerability and exploratory immunogenicity of an investigational RNA-based vaccine for active immunization against malaria” – Sponsor - BioNTech SE.

Folake Olayinka

- Serves as advisor to the WHO-AFRO Regional Immunization Technical Advisory Group. This interest was perceived as non-personal, non-specific and financially insignificant*.
- Serves as Scientific Advisor to the African Local Initiative for Vaccinology Expertise Scientific Advisory Group. This interest was perceived as non-personal, non-specific and financially insignificant*.
- Serves as IA2030 Co chair of Strategic Priority Area 1 (Immunization programs for PHC/UHC. This interest was perceived as non-personal, specific and financially insignificant*.
- Affiliated to US Public Health Institute at USAID Washington DC. This interest was perceived as personal, non-specific and financially significant*.

Hanna Nohynek

- Serves as member to DSMB of COmCov studies of University of Oxford. This interest was assessed as non-personal, specific and financially insignificant*.
- Serves as member to DSMB of the VACCELERATE studies (Covid-19 vaccines immunogenicity and safety in children and elderly. This interest was assessed as non-personal, specific and financially insignificant*.
- Serves as principal investigator on immunogenicity of COVID-19 vaccines, funded by Finnish institute of health and welfare. This interest was perceived as non-personal, specific and financially significant*.
- Her institution (Finnish Institute for Health and Welfare) had received research grants from vaccine manufacturers for phase III and IV studies of influenza vaccines until 2021. This interest was assessed as non-personal, non-specific and financially significant*.
• Served as member of the THL NITAG and gives advises on influenza, covid-19, bird flu, Pnc, pertussis vaccine analyses. This interest was perceived as non-personal, non-specific and financially insignificant*.
• Serves in the Scientific Advisory Group of European Medical Agency on vaccines related matters, Board of Trustees of the International Vaccine Institute, and Board of Trustees of the iccdr.b and Steering Group of the Vaccine Monitoring Platform of the European Medical Agency and European Center for Disease Control. This interest was perceived as personal, non-specific and financially insignificant*.
• Serves as Chief physician in charge of advising Finnish MoH on the matter and giving advice to the Finnish professionals dealing with Covid-19 vaccinations. This interest was perceived as non-personal, specific and financially insignificant*.
• Serves as a member of the ECDC coordinated NITAG network Scientific committee. This interest was perceived as non-personal, non-specific and financially insignificant*.
• Serves as a member of the EMA-ECDC funded Vaccine Monitoring Platform since XII/2022. This interest was perceived as non-personal, non-specific and financially insignificant*.
• Served until 2022 as investigator in an Innovative Medicines Initiative (IMI) funded project DRIVE (Development of Robust and Innovative Vaccine Effectiveness) 2018-23 for influenza vaccine. This interest was perceived as non-personal, non-specific and financially insignificant*.
• Serves as a member in the PROMISE consortium to develop protocols for phase IV studies on RSV vaccines and monoclonal antibodies. This interest was perceived as non-personal, specific and financially insignificant.
• Served until 2021 as Chair of the DSMB of an IMI funded PERISCOPE study on maternal pertussis immunization in the Gambia. This interest was perceived as non-personal, non-specific and financially insignificant*.

Punnee Pitisuttithum

• Serves as a committee member on the Meta DSMB. This interest was perceived as non-personal, non-specific and financially insignificant*.
• Serves as a committee member on the National Advisory committee (ACID). This interest was perceived as non-personal, non-specific and financially insignificant*.
• Serves as principal investigator for the Government Pharmaceuticals Organization, Thailand (GPO)-funded phase I and II Randomized Double Blind Controlled Study to Evaluate the Safety and Immunogenicity of GPO Seasonal Quadrivalent Inactivated Split Virion Influenza Vaccine in Healthy Thais. This interest was perceived as non-personal, non-specific and financially significant*.

• Serves as principal investigator for MHRP/NIH funded on Randomized, Double Blind Evaluation of Late Boost Strategies with IHV01 (FLSC in aluminum phosphate) and A244 with or without ALFQ for HIV-uninfected Participants in RV 306 participants. This interest was perceived as non-personal, non-specific and financially significant*.

• Serves as principal investigator for IVI-CEPI funded on a Phase II/III To Evaluate Safety And Immunogenicity of 2 Dose-Regimen Of BBV87 Chikungunya Vaccine In Healthy Subjects Aged 12 to 65 year. This interest was perceived as non-personal, non-specific and financially significant*.

• Serves as principal investigator for Merck funded HPV Vaccine long term follow up-10 years . This interest was perceived as non-personal, non-specific and financially significant*.

• Serves as a member on the Safety Monitoring Committee for the U.S. Military HIV Research Program (MHRP). This interest was perceived as non-personal, non-specific and financially significant*.

• Serves as principal investigator for the MSD-funded phase III Study the Efficacy, Immunogenicity, and Safety of the 9vHPV vaccine. This interest was perceived as non-personal, non-specific and financially significant*.

• Served until 2023 as principal investigator for the GPO-funded phase III to Evaluate the Immunogenicity and Safety of Tri Fluvac influenza vaccine. This interest was perceived as non-personal, non-specific and financially significant*.

• Served until 2023 as principal investigator for the National Science and Technology Development Agency-funded phase II/III combined Diphtheria-Tetanus-recombinant acellular pertussis (DTaP) vaccine to a licensed DTaP based vaccine (non-recombinant. This interest was perceived as non-personal, non-specific and financially significant*.

• Serves as principal investigator for the government funded phase I/II study of the NDV-HXP-S Covid vaccine. This interest was perceived as non-personal, specific and financially significant*.

• Served until 2023 as principal investigator coordinator for the government funded study of the immunogenicity and safety of the 3rd dose of the ChAdOx-
nCoV19 or BNT162b2 vaccine against COVID-19 vaccine. This interest was perceived as non personal, specific and financially insignificant*.

- Served until 2023 as principal investigator for the Janssen funded phase I/II study of the immunogenicity and safety of the Ad26.CoV2.S heterologous against COVID-19 vaccine. This interest was perceived as non-personal, specific and financially significant*.

- Serves as project chair for the government funded immune responses of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike (NDV-HXP-S) with heterogenous booster after 12 months in adults. This interest was perceived as non-personal, specific and financially significant*. Serves as project chair for the government funded Immune responses, boosting effects of adults previously received two doses of inactivated COV19 vaccines and third doses of any COVID-19 vaccine with additional mRNA COV19 vaccine boost after one year. This interest was perceived as non-personal, specific and financially significant*.

- Serves as project chair for the government funded effectiveness of single dose or two doses of HPV vaccine among adolescents and reproductive women: A test-negative control study. This interest was perceived as non-personal, specific and financially significant*. Serves as project chair for the government funded Effectiveness of the 13-Valent Pneumococcal Conjugated Vaccine Against Community-Acquired Pneumonia in Older Thai Adults: A Matched Case-Control Study. This interest was perceived as non-personal, specific and financially significant*.

Anthony Scott

- Served on the DSMB of Iliad Biotechnologies, Phase 2b trial of Intranasal Pertussis vaccine BPZE1. This interest was assessed as non-personal, non-specific and financially insignificant*.

- Served as a consultant on WHO working group on Vaccines and AMR until 2021. This interest was assessed as non-personal, non-specific and financially insignificant*.

- Serves on the UK Dept of Health and Social Care Joint Committee on Vaccination and Immunisation. This interest was assessed as non-personal, non-specific and financially insignificant*. 
• Serves as principal investigator for the BMGF funded study on fractional doses of PCV in infants in Kenya. This interest was perceived as non-personal, specific and financially significant*.

• Serves as co-investigator for the UK Foreign Commonwealth and development office funded study on COVID-19 vaccine evaluation in Kenya. This interest was perceived as non-personal, specific and financially significant*.

• Serves as principal investigator for the European Union funded study on Vacc-iNTS, Phase I/II trial of NTS vaccine in Kenyan adults. This interest was perceived as non-personal, non-specific and financially significant*.

• Serves as principal investigator for the GAVI funded study on PCVIS -post-licensure study of PCV10 impact, Kenya. This interest was perceived as non-personal, non-specific and financially significant*.

• Received travel grant for organizing ISPPD Toronto in 2022. This interest was perceived as non-personal, non-specific and financially insignificant*.

• His institution receives research support for the following studies. These interests were perceived as non-personal, specific and financially significant*
  o Research grant on cause of child death in Ethiopia (CHAMPS) from Emory University
  o Research grant on surveillance of Meningococcus in Ethiopia from BMGF
  o Research grant on using pneumococcal carriage to inform PCV policy in Africa from wellcome trust
  o Research grant on developing vaccine policy within the UK from National Institute for Health Research

* According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single vaccine manufacturer or other vaccine-related company exceeds 5,000 USD in a calendar year. Likewise, a shareholding in any one vaccine manufacturer or other vaccine-related company in
excess of 1,000 USD would also constitute a “significant shareholding”. As per WHO assessment of conflicts of interests, “Institution” relates only to the expert’s research/or work unit, as subdivision of the department. Funding going to the SAGE member’s research unit needs to be declared.

The above stated SAGE conflicts have been made available for public notice and comment 3 weeks prior to the SAGE meeting in order to provide information on interests or biases relating to potential conflicts of SAGE members. No comments were received.